Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
204.4 USD | -0.53% | +0.83% | -18.74% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 58% by 2026.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company is in a robust financial situation considering its net cash and margin position.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- With an expected P/E ratio at 74.08 and 52.42 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-18.74% | 7.92B | C+ | ||
+73.17% | 12.38B | B- | ||
+16.15% | 7.2B | C- | ||
+4.81% | 5.84B | B | ||
+5.99% | 5.07B | D+ | ||
+27.07% | 4.53B | - | ||
-21.67% | 3.88B | B- | ||
-40.82% | 2.23B | C | ||
+1.49% | 2.02B | - | ||
+5.07% | 1.88B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PEN Stock
- Ratings Penumbra, Inc.